Drug intelligence / Profile preview

TNZ-PB

Development stage: Unknown
Lead developer: Forman Medics
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

TNZ-PB is an oral combination tablet developed by Forman Medics, containing 250 mg of tranexamic acid and 50 mg of pine bark extract. It is formulated to target hyperpigmentation, melasma, and uneven skin tone. Tranexamic acid acts as an antifibrinolytic agent that competitively inhibits plasminogen activation, thereby reducing melanogenesis and UV-induced pigmentation. Pine bark extract provides potent antioxidant and anti-inflammatory support, helping to downregulate tyrosinase activity and other pigmentation-related mediators. Together, these ingredients work synergistically to promote brighter, more even-toned skin.

Brand names: TNZ-PB
Other names: TNZ-PB Tablet

Targets

PLG (Plasminogen)TYR (Tyrosinase)

Beyond the preview

Go deeper on TNZ-PB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNZ-PB.